Month: March 2023

InnovAge Diversifies Board of Directors with New Independent Director

Written by Customer Service on March 30, 2023. Posted in Public Companies.

InnovAge Diversifies Board of Directors with New Independent Director InnovAge announced the appointment of Patty Fontneau to its Board of Directors, effective immediately.DENVER, March 30, 2023 (GLOBE NEWSWIRE) — InnovAge Holding Corp. (“InnovAge”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE), today announced the appointment of Patty Fontneau to its Board of Directors, effective immediately. Fontneau joins InnovAge’s Board as Pavithra Mahesh of Apax Partners and Caroline Dechert of Welsh, Carson, Anderson & Stowe simultaneously step down from their positions with the Board. These changes maintain the participation of the investment firms while adding additional independent and community representation...

PDS Biotech Announces Plan to Initiate Phase 3 Study Evaluating PDS0101 in Combination with KEYTRUDA® in Head and Neck Cancer in 2023

Written by Customer Service on March 30, 2023. Posted in Public Companies.

Company has completed Phase 3 manufacturing of PDS0101 for randomized, controlled, registrational trial in recurrent/metastatic HPV16-positive head and neck cancer FLORHAM PARK, N.J., March 30, 2023 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, announced that it has completed key tech transfer, scale up and manufacturing activities required to initiate a global, multicenter Phase 3 registrational trial investigating the combination of PDS0101 and KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in the fourth quarter of 2023. The Phase 3 trial, named VERSATILE-003, will investigate the combination compared to KEYTRUDA® monotherapy for the treatment of unresectable, recurrent/metastatic...

PureFacts Announces Acquisition of Xtiva Financial Systems, Becoming the Most Complete Revenue Management Solution for the Wealth Management Industry

Written by Customer Service on March 30, 2023. Posted in Mergers And Acquisitions.

Xtiva grows PureFacts’ platform with cutting-edge technologies and expertise in incentive compensation management. TORONTO, March 30, 2023 (GLOBE NEWSWIRE) — PureFacts Financial Solutions, a leader in revenue management, enterprise reporting, and insights solutions for the asset and wealth management sector, announced today that is has acquired Xtiva Financial Systems, Inc. (Xtiva), the global leader in sales performance and incentive compensation management software for the wealth management industry. This acquisition marks a significant milestone in PureFacts’ growth strategy and reinforces its commitment to delivering exceptional, seamless, end-to-end revenue management solutions to its clients. “We’re thrilled to welcome Xtiva to the PureFacts family,” said Robert Madej, Founder, and CEO of PureFacts. “From day one, we have...

edgeTI Hires Social Media Firm Outside the Box Capital

Written by Customer Service on March 30, 2023. Posted in Public Companies.

Effort to Increases News Flow to Investors via Social Media ARLINGTON, Va., March 30, 2023 (GLOBE NEWSWIRE) — Edge Total Intelligence Inc. (“edgeTI” or the “Company”) (TSXV: CTRL, OTCQB: UNFYF, FSE: Q5i), is pleased to announce it has engaged Toronto-based marketing firm Outside the Box Capital, the acquired and rebranded firm of former North Equities Corp. to provide marketing services via social media channels to investors. Outside the Box Capital specializes in social media platforms and will be able to facilitate greater awareness and widespread dissemination of the Company’s news into these channels. “We strive to support companies with an under told story that are doing something extremely innovative,” said Jason Coles, CEO of Outside the Box Capital. “We are thrilled to be working alongside edgeTI during this exciting...

Global FMCG Logistics Market Size Worth USD 131.54 Billion, Globally, by 2028 at a CAGR of 3.15%

Written by Customer Service on March 30, 2023. Posted in Mergers And Acquisitions.

The FMCG logistics market size is projected to reach USD 131.54 billion in 2028, at compound annual growth rate (CAGR) of 3.15% during the forecast period 2021 to 2028. The FMCG logistics industry was USD 103.57 billion in 2020. Pune, India, March 30, 2023 (GLOBE NEWSWIRE) — The global FMCG logistics market size was USD 103.57 billion in 2020 & market is projected to grow from USD 105.85 billion in 2021 to USD 131.54 billion in 2028 at a CAGR of 3.15% during the 2021-2028 period. Fortune Business Insights™ published this information in its report titled, “FMCG Logistics Market, 2021-2028.” According to our analysts, proper management through the supply chain activities in each region, storage and transportation services helps the FMCG logistics industry achieve its business goal. KEY INDUSTRY DEVELOPMENTS: May 2021:...

Tire Bead Wire Market Size to Reach $2.5 Billion by 2031: Allied Market Research

Written by Customer Service on March 30, 2023. Posted in Mergers And Acquisitions.

Rapid industrialization and urbanization, rising sales of passenger cars and commercial vehicles in both established & emerging economies, increase in disposable income, and surge in demand for electric cars drive the growth of the tire bead wire market. By type, the regular tensile strength (1770-2200 MP) segment contributed to the major share in 2021. By region, LAMEA would showcase the fastest CAGR by 2031. Portland, OR, March 30, 2023 (GLOBE NEWSWIRE) — According to the report published by Allied Market Research, the global tire bead wire market generated $1.2 billion in 2021, and is estimated to reach $2.5 billion by 2031, witnessing a CAGR of 8.3% from 2022 to 2031. The report offers a detailed analysis of changing market trends, top segments, key investment pockets, value chains, regional landscapes, and competitive...

EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative Diseases

Written by Customer Service on March 30, 2023. Posted in Mergers And Acquisitions.

Combined company will pursue late-stage clinical development of oral neflamapimod for the treatment of dementia with Lewy bodies EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging Combined company expected to have a cash runway through Phase 2b clinical data and to the end of 2024 Transaction has unanimous support of both EIP Pharma and Diffusion Boards of Directors BOSTON and CHARLOTTESVILLE, Va., March 30, 2023 (GLOBE NEWSWIRE) — EIP Pharma Inc. (EIP Pharma), a privately held clinical-stage company focused on developing treatments for neurodegenerative diseases, and Diffusion Pharmaceuticals Inc. (Diffusion or Diffusion Pharmaceuticals) (NASDAQ: DFFN), today announced that the companies have entered into a definitive merger agreement for an all-stock...

Centessa Pharmaceuticals Reports Recent Business Progress and Financial Results for the Fourth Quarter and Full-Year 2022

Written by Customer Service on March 30, 2023. Posted in Earnings Releases And Operating Results.

– Initiated registration program for SerpinPC to treat hemophilia B; Enrolling subjects in PRESent-5, observational study – – First subject dosed in Phase 1/2a clinical trial for LB101, a PD-L1xCD47 LockBody® to treat solid tumors; Preclinical data from second LockBody program targeting PD-L1xCD3 expected in 2023 – – Nominated ORX750, an orally administered, selective orexin receptor-2 (OX2R) agonist, as product candidate with the potential to be a best-in-class therapy to treat narcolepsy and other sleep disorders; ORX750 profile to be presented at scientific meeting in 2023 – – Cash runway into 2026 – BOSTON and LONDON, March 30, 2023 (GLOBE NEWSWIRE) — Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients,...

Renalytix Reports Second Quarter and First Half Fiscal Year 2023 Financial Results

Written by Customer Service on March 30, 2023. Posted in Earnings Releases And Operating Results.

LONDON and SALT LAKE CITY, March 30, 2023 (GLOBE NEWSWIRE) — Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the fiscal second quarter and first half ended December 31, 2022. Recent Highlights (including post period events)Expanded insurance coverage for KidneyIntelX including:One of the largest not-for-profit health insurers covering over three million lives in the Northeast U.S. Largest private payer in Illinois with over eight million members 35 state Medicaid plans including recent additions of Texas and FloridaAchieved Medicare payment for KidneyIntelX through the individual claims review (ICR) process...

Stran & Company Achieves 48.5% Increase in Revenue for the 2022 Fiscal Year and Returns to Profitability for the Fourth Quarter of 2022

Written by Customer Service on March 30, 2023. Posted in Earnings Releases And Operating Results.

Achieves Record Revenue of $18.3 million and Net Income of $903,000 for the Fourth Quarter of 2022 Conference call to be held today at 10:00 AM ET QUINCY, Mass., March 30, 2023 (GLOBE NEWSWIRE) — Stran & Company, Inc. (“Stran” or the “Company”) (NASDAQ: SWAG) (NASDAQ: SWAGW), a leading outsourced marketing solutions provider that leverages its promotional products and loyalty incentive expertise, today provided a business update and reported financial results for the year ended December 31, 2022. Andy Shape, President and CEO of Stran, commented, “Throughout 2022, we continued to grow and generated revenue of approximately $59.0 million for the 2022 fiscal year, a 48.5% increase compared to 2021. Importantly, we returned to profitability for the fourth quarter of 2022, generating approximately $18.3...

Month: March 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals